VRTX Stock Summary and Trading Ideas (Vertex Pharmaceuticals | NASDAQ:VRTX)

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Vertex Pharmaceuticals trades on the NASDAQ stock market under the symbol VRTX.

As of January 12, 2026, VRTX stock price declined to $460.59 with 1,050,632 million shares trading.

VRTX has a beta of 0.21, meaning it tends to be less sensitive to market movements. VRTX has a correlation of 0.01 to the broad based SPY ETF.

VRTX has a market cap of $116.86 billion. This is considered a Large Cap stock.

Last quarter Vertex Pharmaceuticals reported $3 billion in Revenue and $4.80 earnings per share. This beat revenue expectation by $24 million and exceeded earnings estimates by $.45.

In the last 3 years, VRTX traded as high as $519.88 and as low as $282.58.

The top ETF exchange traded funds that VRTX belongs to (by Net Assets): VTI, VOO, QQQ, IVV, SPY.

VRTX has underperformed the market in the last year with a price return of +11.8% while the SPY ETF gained +19.2%. However, in the short term, VRTX had mixed performance relative to the market. It has outperformed in the last 3 months, returning +11.0% vs +3.9% return in SPY. But in the last 2 weeks, VRTX shares have been beat by the market, returning -0.5% compared to an SPY return of +0.7%.

VRTX support price is $457.26 and resistance is $470.46 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VRTX shares will trade within this expected range on the day.